TPG Acquires 35% Stake in SCHOTT Poonawalla from Serum Institute

TPG, a global alternative asset management firm, has agreed to acquire a 35% stake in SCHOTT Poonawalla, the joint venture between SCHOTT Pharma and Serum Institute of India (SII), with Novo Holdings participating as a co-investor. SII will retain a minority stake following the deal, which is expected to close in the first half of 2025, pending customary conditions. The partnership aims to strengthen SCHOTT Poonawalla’s growth by leveraging TPG's healthcare investment experience and global network, enhancing its ability to meet rising demand for advanced drug containment and delivery solutions. SCHOTT Poonawalla’s product portfolio includes cartridges for auto-injector pens, prefillable syringes, vials, ampoules, and regulatory and manufacturing services for the pharmaceutical and biotech sectors. Leaders from both SII and SCHOTT Poonawalla emphasized that the collaboration with TPG will support innovation and supply chain resilience as they pursue long-term global ambitions. The investment is seen as a significant milestone for SCHOTT Poonawalla's expansion and market leadership in pharmaceutical packaging.